Search Results

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the “Company” or “Biohaven”) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. (“Kleo”) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab

Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleo’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform.

Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present today to local stakeholders at the Bioscience Pipeline & Innovation in Connecticut in the Age of COVID conference on Monday, September 21, 2020 at 2:00 p.m. ET

Kleo Pharmaceuticals announced today that Doug Manion, MD, Chief Executive Officer and Chairman of the Board, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium . Presentation Details: Date: August 5, 2020 Time: 8:30am Eastern Time About Kl

Kleo is a novel immuno-oncology company spun out of Yale University developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics

Kleo Pharmaceuticals, Inc. announced that its Chief Executive Officer Doug Manion, MD, will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.

United Spinal Association has announced the appointment of Kleo J. King, a legal advisor and attorney specializing in accessible housing, transportation, and public accommodations, as Senior Director of Accessibility Operations and Counsel.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced that it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 4:00 p.m. ET.

Synergistic Potential of Kleo’s Antibody Recruiting Molecule (ARM™) and Celularity’s Placental-Derived NK Cells to Be Evaluated in the Context of COVID-19 and Multiple Myeloma